EA201790072A1 - Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы - Google Patents

Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы

Info

Publication number
EA201790072A1
EA201790072A1 EA201790072A EA201790072A EA201790072A1 EA 201790072 A1 EA201790072 A1 EA 201790072A1 EA 201790072 A EA201790072 A EA 201790072A EA 201790072 A EA201790072 A EA 201790072A EA 201790072 A1 EA201790072 A1 EA 201790072A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
treatment
trpm8
tiazole
neuralgia
Prior art date
Application number
EA201790072A
Other languages
English (en)
Other versions
EA034525B1 (ru
Inventor
Андреа Арамини
Жанлука Бианчини
Лаура Брандолини
Андреа Беккарди
Самуеле Лиллини
Джузеппе Нано
Original Assignee
Домпе Фармачеутичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Домпе Фармачеутичи С.П.А. filed Critical Домпе Фармачеутичи С.П.А.
Publication of EA201790072A1 publication Critical patent/EA201790072A1/ru
Publication of EA034525B1 publication Critical patent/EA034525B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/42—One oxygen atom attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Заявленное изобретение относится к соединениям, действующим в качестве селективных антагонистов 8 члена подсемейства М катионного канала Транзиторного Рецепторного Потенциала (TRPM8) и имеющим формулу (I).Упомянутые соединения применяют в лечении болезней, связанных с активностью TRPM8, таких как боль, воспаление, ишемия, нейродегенерация, инсульт, психические расстройства, зуд, заболевания раздраженной толстой кишки, вызванные простудой и/или обострившиеся респираторные нарушения и урологические расстройства.
EA201790072A 2014-06-23 2015-06-23 Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы EA034525B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173502 2014-06-23
PCT/EP2015/064146 WO2015197640A1 (en) 2014-06-23 2015-06-23 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma

Publications (2)

Publication Number Publication Date
EA201790072A1 true EA201790072A1 (ru) 2017-11-30
EA034525B1 EA034525B1 (ru) 2020-02-17

Family

ID=50979632

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790072A EA034525B1 (ru) 2014-06-23 2015-06-23 Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы

Country Status (21)

Country Link
US (2) US10196368B2 (ru)
EP (1) EP3157918B1 (ru)
JP (1) JP6557332B2 (ru)
KR (1) KR102493005B1 (ru)
CN (1) CN106660975B (ru)
AU (1) AU2015279272B2 (ru)
CY (1) CY1121624T1 (ru)
DK (1) DK3157918T3 (ru)
EA (1) EA034525B1 (ru)
ES (1) ES2724111T3 (ru)
HR (1) HRP20190819T1 (ru)
HU (1) HUE043586T2 (ru)
LT (1) LT3157918T (ru)
MA (1) MA39912B1 (ru)
ME (1) ME03399B (ru)
PL (1) PL3157918T3 (ru)
PT (1) PT3157918T (ru)
RS (1) RS58590B1 (ru)
SI (1) SI3157918T1 (ru)
TR (1) TR201905319T4 (ru)
WO (1) WO2015197640A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69122084T2 (de) 1990-11-30 1997-04-03 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
CA2583015A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007017094A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007080109A1 (en) 2006-01-16 2007-07-19 Bayer Healthcare Ag Substituded benzyloxy-phenylmethylurea derivatives
US7897781B2 (en) 2006-05-10 2011-03-01 Janssen Pharmaceutica Nv Cold menthol receptor-1 antagonists
JP5539868B2 (ja) 2007-07-18 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｍ８モジュレーターとしてのスルホンアミド類
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
KR20140071518A (ko) 2009-05-01 2014-06-12 라퀄리아 파마 인코포레이티드 Ｔｒｐｍ8 길항제로서의 설파모일 벤조산 유도체
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
PT2793883T (pt) * 2011-12-19 2018-07-18 Dompe Farm Spa Antagonistas de trpm8

Also Published As

Publication number Publication date
JP6557332B2 (ja) 2019-08-07
RS58590B1 (sr) 2019-05-31
AU2015279272B2 (en) 2018-01-18
KR102493005B1 (ko) 2023-01-30
ES2724111T3 (es) 2019-09-06
LT3157918T (lt) 2019-05-27
CY1121624T1 (el) 2020-07-31
US20170190678A1 (en) 2017-07-06
MA39912B1 (fr) 2019-05-31
PT3157918T (pt) 2019-05-09
TR201905319T4 (tr) 2019-05-21
US20190106395A1 (en) 2019-04-11
US10196368B2 (en) 2019-02-05
CN106660975B (zh) 2019-12-31
EP3157918B1 (en) 2019-03-27
US11046662B2 (en) 2021-06-29
PL3157918T3 (pl) 2019-08-30
AU2015279272A2 (en) 2017-01-19
MA39912A (fr) 2017-04-26
SI3157918T1 (sl) 2019-05-31
CN106660975A (zh) 2017-05-10
HUE043586T2 (hu) 2019-08-28
AU2015279272A1 (en) 2017-01-12
ME03399B (me) 2020-01-20
JP2017520623A (ja) 2017-07-27
KR20170031664A (ko) 2017-03-21
EA034525B1 (ru) 2020-02-17
WO2015197640A1 (en) 2015-12-30
EP3157918A1 (en) 2017-04-26
HRP20190819T1 (hr) 2019-06-28
DK3157918T3 (da) 2019-05-13

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
TR201901886T4 (tr) DNA-PK inhibitörleri.
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201491213A1 (ru) Антагонисты trpm8
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201891710A1 (ru) Терапевтические соединения
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201790072A1 (ru) Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
EA201791881A1 (ru) Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.